CAS 172822-29-6
:Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
7 produits concernés.
Aprepitant Related Compound B (3-[[(2S,3R)-2-[(S)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholino]methyl]-1H-1,2,4-triazol-5(4H)-one)
CAS :Nucleic acids and their salts, whether or not chemically defined; other heterocyclic compounds, nesoiFormule :C23H21F7N4O3Couleur et forme :White Off-White Crystalline PowderMasse moléculaire :534.15019ent-Aprepitant
CAS :Formule :C23H21F7N4O3Couleur et forme :White To Off-White SolidMasse moléculaire :534.433-[[(2S,3R)-2-[(S)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholino]methyl]-1H-1,2,4-triazol-5(4H)-one ((S,R,S)-Aprepitant)
CAS :Produit contrôléFormule :C23H21F7N4O3Couleur et forme :NeatMasse moléculaire :534.43ent-aprepitant
CAS :<p>Aprepitant is a drug that belongs to the class of antiemetics. It is an antagonist of the neurokinin-1 receptor (NK-1R) and blocks the apical portion of the NK-1R, preventing binding of substance P. Aprepitant also has been shown to have a matrix effect on human pharmacokinetics in vitro and to inhibit p450 activity in human serum. This drug has been found to induce apoptosis by inhibiting the expression of pro-apoptotic proteins and activating pro-survival proteins. Aprepitant has also been shown to be effective in treating solid tumours, particularly colorectal cancer, with synergism with chemotherapy drugs such as trifluoroacetic acid.</p>Formule :C23H21F7N4O3Degré de pureté :Min. 95%Couleur et forme :White To Off-White SolidMasse moléculaire :534.43 g/molent-Aprepitant-13C15N2
CAS :Produit contrôléFormule :CC22H21F715N2N2O3Couleur et forme :NeatMasse moléculaire :537.406ent-Aprepitant
CAS :Produit contrôléFormule :C23H21F7N4O3Couleur et forme :NeatMasse moléculaire :534.43
![3-[[(2S,3R)-2-[(S)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholino]methyl]-…](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2F86%2Fthumb%2FMM3251.02.jpg&w=3840&q=75)
